E
SONM icon

Ergoteles’s DNA X Inc SONM Stock Holding History

Ergoteles’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-139
Closed -$21K – 1972
2022
Q1 		$21K Buy
+139
New +$18.8K ﹤0.01% 1158

Other funds holding SONM

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Ergoteles's SONM Position: Q2 2022 in Review

Ergoteles sold out of DNA X Inc (SONM) in Q2 2022, closing a stake of 139 shares — an estimated $21K sold.

Ergoteles first reported a position in SONM in Q1 2022 and held it in 1 quarter. The position peaked at $21K in Q1 2022. 12 funds tracked by Wall St. Rank hold SONM as of Q2 2022.

  • Ergoteles reported no remaining DNA X Inc position as of Q2 2022 after selling out during the quarter.
  • Ergoteles sold 139 DNA X Inc shares in Q2 2022, an estimated $21K.
  • Ergoteles first reported a position in DNA X Inc in Q1 2022 and held it in 1 quarter.
  • Ergoteles's DNA X Inc position peaked at $21K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held DNA X Inc as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.